Estrella Immunopharma, Inc.

ESLA Nasdaq CIK: 0001844417

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
Business Address 5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
Mailing Address 5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
Phone (510) 318-9098
Fiscal Year End 1231
EIN 861314502

Financial Overview

FY2024

-$11.11M
Net Income
$4.17M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
S-1/A IPO registration amendment January 22, 2026 View on SEC
S-1/A IPO registration amendment January 16, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
424B5 Prospectus supplement January 6, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
S-1 IPO registration statement December 22, 2025 View on SEC
8-K Current report of material events December 4, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC
8-K Current report of material events November 6, 2025 View on SEC
3 Initial insider ownership report October 1, 2025 View on SEC

Material Events

8-K Legal Issue January 13, 2026
High Impact
  • The company has 45 calendar days to submit a compliance plan to Nasdaq.
  • Estrella Immunopharma plans to hold its annual shareholder meeting in April 2026.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.